Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P07949: Variant p.Val804Met

Proto-oncogene tyrosine-protein kinase receptor Ret
Gene: RET
Feedback?
Variant information Variant position: help 804 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Methionine (M) at position 804 (V804M, p.Val804Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MTC; familial form; faster autophosphorylation and activation, leading to enhanced activity; confers resistance to vandetanib, lenvatinib, cabozantinib and nintedanib inhibitors. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 804 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1114 The length of the canonical sequence.
Location on the sequence: help HPHVIKLYGACSQDGPLLLI V EYAKYGSLRGFLRESRKVGP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGP

Mouse                         HPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRDSRKIGP

Rat                           HPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRDSRKIGP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 29 – 1114 Proto-oncogene tyrosine-protein kinase receptor Ret
Chain 708 – 1017 Soluble RET kinase fragment
Topological domain 658 – 1114 Cytoplasmic
Domain 724 – 1016 Protein kinase
Modified residue 806 – 806 Phosphotyrosine; by autocatalysis
Modified residue 809 – 809 Phosphotyrosine; by autocatalysis
Mutagenesis 708 – 1114 Missing. Loss of induced cell death, but increased cell aggregation.
Beta strand 801 – 805



Literature citations
Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
Plaza-Menacho I.; Barnouin K.; Goodman K.; Martinez-Torres R.J.; Borg A.; Murray-Rust J.; Mouilleron S.; Knowles P.; McDonald N.Q.;
Mol. Cell 53:738-751(2014)
Cited for: X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 705-1013 IN COMPLEX WITH ADENOSINE; FUNCTION; CATALYTIC ACTIVITY; PHOSPHORYLATION AT TYR-687; TYR-826; TYR-900; TYR-905; TYR-981; TYR-1015; TYR-1029 AND TYR-1062; MUTAGENESIS OF GLU-734; LYS-758; ARG-912 AND ILE-913; VARIANT MEN2B THR-918; CHARACTERIZATION OF VARIANT MEN2B THR-918; VARIANT MTC MET-804; CHARACTERIZATION OF VARIANT MTC MET-804; A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma.
Fattoruso O.; Quadro L.; Libroia A.; Verga U.; Lupoli G.; Cascone E.; Colantuoni V.;
Hum. Mutat. Suppl. 1:S167-S171(1998)
Cited for: VARIANT MTC MET-804; A RET double mutation in the germline of a kindred with FMTC.
Bartsch D.K.; Hasse C.; Schug C.; Barth P.; Rothmund M.; Hoeppner W.;
Exp. Clin. Endocrinol. Diabetes 108:128-132(2000)
Cited for: VARIANTS MTC MET-804 AND LEU-844; Drug resistance profiles of mutations in the RET kinase domain.
Liu X.; Shen T.; Mooers B.H.M.; Hilberg F.; Wu J.;
Br. J. Pharmacol. 175:3504-3515(2018)
Cited for: ACTIVITY REGULATION; VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998; CHARACTERIZATION OF VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998; VARIANTS MTC LEU-804; MET-804 AND THR-918; CHARACTERIZATION OF VARIANTS MTC LEU-804; MET-804 AND THR-918;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.